Last week, the company updated its revenue guidance to $72 million to $74 million for FY 2015.
EndoChoice stock has a 52-week high of $19.69 and a 52-week low of $7.37, according to the report.
More articles on gastroenterology:
Exact Sciences to open biotech campus & more – 3 GI company key notes
CMS cuts to colonoscopy reimbursement finalized: 3 things to know
6 recent must-reads on CRC screening & treatments
